MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Influenza virus strains show increasing drug resistance

Back to infectious disease news Blogs list Cancer blog  


Subscribe To Infectious Disease News RSS Feed  RSS content feed What is RSS feed?

Influenza virus strains show increasing drug resistance




Two new studies raise public health concerns about increasing antiviral resistance among certain influenza viruses, their ability to spread, and a lack of alternative antiviral therapy options. The findings appear in the January 1 issue of The Journal of Infectious Diseases (Please see below for links to these articles online.).



Influenza virus strains show increasing drug resistance

Influenza viruses are treated with two classes of drugs: M2 blockers (adamantanes) and neuraminidase inhibitors (NAIs), including oseltamivir and zanamivir. While the spread of influenza strains with resistance to one class of drugs has been well documented in recent years, a new report from Larisa Gubareva, MD, PhD and his colleagues at the Centers for Disease Control and Prevention (CDC) and at health agencies in West Virginia, Texas, and Canada, confirms that dual resistance can emerge in several ways and has been on the rise during the past three years.

The study analyzed 28 seasonal H1N1 viruses with dual resistance from 2008 to 2010 from five countries, revealing that additional antiviral resistance could rapidly develop in a previously single-resistant strain as a result of mutation, drug response, or gene exchange with another virus.

Eventhough dual resistant viruses are still rare, the researchers noted an increase in the number of tested viruses with this resistance, from 0.06 percent (2007-2008) to 1.5 percent (2008-2009) to 28 percent (2009-2010); however, during the 2009-2010 season the number of circulating seasonal H1N1 viruses was low, and only 25 viruses were tested. "Because only two classes of antiviral agents are approved, the detection of viruses with resistance to drugs in both classes is concerning," said Dr. Gubareva. "If circulation of viruses with dual resistance becomes more widespread among any of the predominant circulating influenza A viruses, therapy options will be extremely limited. New antiviral agents and strategies for antiviral treatment are likely to be necessary in the future".

A second study, conducted by Catherine Moore and his colleagues in the United Kingdom, examined an outbreak of oseltamivir resistant (OR) pandemic H1N1 infection in a hematology unit in the UK. The study is the first to confirm person-to-person transmission of this dually resistant strain through molecular epidemiologic methods. The 2009 pandemic H1N1 virus was inherently resistant to adamantine, but was susceptible to and treated with oseltamivir. However, by October 2009, emergence of OR H1N1 had been documented in rare patients on oseltamivir treatment.

In the hematology unit that Moore and his colleagues studied, eight of the 11 pandemic H1N1 virus infections were resistant to oseltamivir, with half of those cases resulting from direct transmission of the resistant virus. Immunocompromised patients were more susceptible to the emergence of OR H1N1 virus on therapy and also transmitted the virus to others, despite often having no influenza symptoms or having completed antiviral treatment. As a result, the screening of patients for OR H1N1 viruses became especially important, and therapy guidelines were altered to include therapy with zanamivir, to which the viruses remained susceptible.

"These findings suggest that oseltamivir may not be the frontline drug of choice in hematology patients, and zanamivir may prove to be more beneficial," the study authors wrote. "Guidelines may need to be changed to include active screening for the [OR] mutation in hematology patients diagnosed with H1N1 and other patients who are immunocompromised when oseltamivir is used." If high risk groups are more actively monitored, early diagnosis will help prevent the spread of H1N1 viruses, and proper screening for infection and resistance will aid in making proper therapeutic decisions.

In an accompanying editorial, Frederick G. Hayden, MD, of the University of Virginia School of Medicine, and Menno D. de Jong, MD, of the University of Amsterdam in the Netherlands, agreed that increasingly detailed monitoring and creative preventive and therapeutic choices will be mandatory as unpredictable and antiviral-resistant influenza viruses continue to appear. This is particularly true "given our current paucity of therapeutic choices," as per the authors. With only two drug classes approved in the U.S. and most countries for treating influenza virus, future research should focus on the effectiveness of zanamivir and combination antiviral treatment and the need to develop new antivirals with unique mechanisms of action.

"Such information will ensure rapid development and testing of alternative antiviral strategies for use in immunocompromised hosts and seriously ill hospitalized patients to address their unmet medical needs and the associated public health concerns, especially the continuing threat of antiviral resistance," the authors conclude.


Posted by: Mark    Source




Did you know?
Two new studies raise public health concerns about increasing antiviral resistance among certain influenza viruses, their ability to spread, and a lack of alternative antiviral therapy options. The findings appear in the January 1 issue of The Journal of Infectious Diseases (Please see below for links to these articles online.).

Medicineworld.org: Influenza virus strains show increasing drug resistance

SARS Main| SARS Abroad| SARS and Goverment| SARS Information in different languages| Media about SARS| Physicians resources for SARS| Reference information for SARS| Updates on SARS|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.